ClinicalTrials.gg
Not yet recruitingNCT07817953Updated Sep 14, 2026

AVF Awareness Among Advanced CKD Patients

An observational study in Chronic Kidney Diseases, Dialysis; Complications and Arteriovenous Fistula, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assiut University · Observational

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
116
Ages
18 Years and older
Sex
All
01

Study summary

This cross-sectional study aims to assess awareness regarding arteriovenous fistula creation among patients with advanced chronic kidney disease, including pre-dialysis patients and those receiving maintenance hemodialysis, at Assiut University Hospital.

Read the detailed description

Timely creation of arteriovenous fistula (AVF) is preferred for patients requiring maintenance hemodialysis. Many patients in Egypt initiate hemodialysis with temporary catheters. This hospital-based cross-sectional study will assess the level of knowledge regarding AVF creation among adults with advanced CKD (stage 4-5 not on dialysis and patients on maintenance hemodialysis).

A structured interviewer-administered questionnaire will be used to evaluate current awareness in pre-dialysis patients and retrospectively assessed pre-dialysis awareness in current hemodialysis patients.

02

Conditions studied

  • Chronic Kidney Diseases
  • Dialysis; Complications
  • Arteriovenous Fistula
  • Kidney Failure, Chronic

Browse trials for

Keywords

  • Arteriovenous fistula
  • AVF awareness
  • Hemodialysis
  • Chronic kidney disease
  • Vascular access
  • Assiut
03

In context

Kidney Failure, Chronic Reclassified

2,108 studies on the registry are indexed under Kidney Failure, Chronic; 273 are open to participants now.

This study's planned enrollment of 116 is close to the median of 120 across 442 observational studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with advanced chronic kidney disease (CKD stage 4-5 not on maintenance hemodialysis or currently receiving maintenance hemodialysis) attending the Nephrology Unit and Maintenance Hemodialysis Unit of Assiut University Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Documented chronic kidney disease
  • CKD stage 4-5 not on maintenance hemodialysis OR currently on maintenance hemodialysis for established CKD
  • Able to understand and answer the questionnaire
  • Written

Exclusion criteria

Exclusion Criteria:

  • Acute kidney injury without established CKD
  • Previous kidney transplantation (if considered to affect homogeneity)
  • Severe cognitive or communication impairment preventing reliable questionnaire completion
  • Unable or unwilling to provide
  • Inability to provide reasonably reliable information about the pre-dialysis period (for retrospective questions)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
116 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes

Groups and cohorts

  • Single cohort: Adults with advanced CKD

    Adults with advanced chronic kidney disease (pre-dialysis stage 4-5 and maintenance hemodialysis patients) who will complete a structured questionnaire assessing awareness of arteriovenous fistula creation.

06

What researchers measure

Primary outcomes

  1. Pre-dialysis AVF awareness score

    Mean score of knowledge regarding arteriovenous fistula creation (including its use for hemodialysis, need for pre-dialysis preparation, maturation time, arm protection, and differences from catheter) assessed by a structured questionnaire. For patients already on maintenance hemodialysis, awareness will be assessed retrospectively for the period before dialysis initiation.

    Time frame: Baseline

Secondary outcomes

  1. Proportion with prior AVF counseling

    Percentage of participants who report receiving counseling about arteriovenous fistula before initiation of maintenance hemodialysis.

    Time frame: Baseline

  2. Vascular access used at first hemodialysis session

    Percentage of maintenance hemodialysis patients who started dialysis with arteriovenous fistula versus temporary central venous catheter.

    Time frame: Baseline

  3. Timing of AVF creation

    Percentage of participants in whom arteriovenous fistula was created before versus after initiation of maintenance hemodialysis.

    Time frame: Baseline

  4. Willingness to undergo AVF creation

    Percentage of participants willing to undergo arteriovenous fistula creation when indicated.

    Time frame: Baseline

  5. Sources of AVF information

    Distribution of reported sources of information about arteriovenous fistula (nephrologist, nurse, family, other patients, or media).

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Yuan S, Hu D, Gao D, Butch CJ, Wang Y, Zheng H, Sheng Z. Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier. J Nanobiotechnology. 2025 Jul 8;23(1):493. doi: 10.1186/s12951-025-03572-y. PubMed 40624508 ↗
  • Cavanaugh KL, Wingard RL, Hakim RM, Elasy TA, Ikizler TA. Patient dialysis knowledge is associated with permanent arteriovenous access use in chronic hemodialysis. Clin J Am Soc Nephrol. 2009 May;4(5):950-6. doi: 10.2215/CJN.04580908. Epub 2009 Apr 23. PubMed 19389825 ↗
  • Shamasneh AO, Atieh AS, Gharaibeh KA, Hamadah A. Perceived barriers and attitudes toward arteriovenous fistula creation and use in hemodialysis patients in Palestine. Ren Fail. 2020 Nov;42(1):343-349. doi: 10.1080/0886022X.2020.1748650. PubMed 32338112 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 14, 2026
StartEst.
Sep 10, 2026
Primary completionEst.
Sep 10, 2027
CompletionEst.
Feb 20, 2028
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07817953
Lead sponsor
Assiut University
Responsible party
Boliss Sydhom Henain Ragheb (Resident Physician, Assiut University) — Principal investigator
First posted
Sep 14, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Sep 10, 2027 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
Sep 14, 2026

Study contacts

Boliss s Ragheb, Resident
Contact
Poles18313386@med.aun.edu.eg
+201003957926
Mohamed A Abozaid, prof
study chair · Internal Medicine Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion